Key points are not available for this paper at this time.
Semaglutide and SGLT-2 inhibitors conferred reductions both in body weight and blood pressure that were sustainable for over 1 year of treatment. These agents may be preferable treatment options for patients with type 2 diabetes who are overweight/obese and/or hypertensive.
Building similarity graph...
Analyzing shared references across papers
Loading...
Απόστολος Τσάπας
Aristotle University of Thessaloniki
Thomas Karagiannis
Aristotle University of Thessaloniki
Panagiota Kakotrichi
Aristotle University of Thessaloniki
Diabetes Obesity and Metabolism
University of Oxford
Aristotle University of Thessaloniki
Churchill Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Τσάπας et al. (Fri,) studied this question.
synapsesocial.com/papers/69df7d481113c054a47a167d — DOI: https://doi.org/10.1111/dom.14451